Accelerating Biologics Manufacturing by Modeling or: Is Approval under the QbD and PAT Approaches Demanded by Authorities Acceptable without a Digital-Twin?
Zobel-Roos, S.; Schmidt, A.; Mestmäcker, F.; Mouellef, M.; Huter, M.; Uhlenbrock, L.; Kornecki, M.; Lohmann, L.; Ditz, R.; Strube, J. Accelerating Biologics Manufacturing by Modeling or: Is Approval under the QbD and PAT Approaches Demanded by Authorities Acceptable without a Digital-Twin? Processes 2019, 7, 94. https://doi.org/10.3390/pr7020094
Zobel-Roos S, Schmidt A, Mestmäcker F, Mouellef M, Huter M, Uhlenbrock L, Kornecki M, Lohmann L, Ditz R, Strube J. Accelerating Biologics Manufacturing by Modeling or: Is Approval under the QbD and PAT Approaches Demanded by Authorities Acceptable without a Digital-Twin? Processes. 2019; 7(2):94. https://doi.org/10.3390/pr7020094
Chicago/Turabian StyleZobel-Roos, Steffen; Schmidt, Axel; Mestmäcker, Fabian; Mouellef, Mourad; Huter, Maximilian; Uhlenbrock, Lukas; Kornecki, Martin; Lohmann, Lara; Ditz, Reinhard; Strube, Jochen. 2019. "Accelerating Biologics Manufacturing by Modeling or: Is Approval under the QbD and PAT Approaches Demanded by Authorities Acceptable without a Digital-Twin?" Processes 7, no. 2: 94. https://doi.org/10.3390/pr7020094